Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367537 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29396701 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL30517362 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29359151 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31593 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1231880 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10290527 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29930052 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL903333 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL42030 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN S A U (ES) | 2026-05-21 | — | — | US | disclosed |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | CURIA SPAIN, S.A.U. (ES) | 2026-02-17 | — | — | US | disclosed |
| CN-115151529-B | Processes and intermediates for preparing Wu Pati n | 库里亚西班牙公司 | 2025-04-22 | — | — | CN | disclosed |
| US-12084456-B2 | Isocarbostyril alkaloids and functionalization thereof | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230139156-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CURIA SPAIN, S.A.U. (ES) | 2023-05-04 | — | — | US | disclosed |
| EP-4077276-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | Curia Spain S.A.U. (ES) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260138946-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | JAK1, JAK3, JAK2 | CA1 3030/4885CA2 2621/4885CA7 2115/4885 |
| US-20230139156-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF UPADACITINIB | CDK19, CDK11B, CDK9 | CA1 4046/4885CA2 4106/4885CA7 2630/4885 |
| US-12084456-B2 | Isocarbostyril alkaloids and functionalization thereof | NISCH, CIAPIN1, CA7 | CA1 625/4885CA2 1515/4885CA7 3/4885 |
| US-12552746-B2 | Process and intermediates for the preparation of upadacitinib | JAK1, JAK3, MET | CA1 2705/4885CA2 2570/4885CA7 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.